SCHEMBL12102920

SCHEMBL12102920

Cc1cc(Nc2cc(C)nc(Sc3ccc(N)cc3)n2)[nH]n1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AURKA O14965 8/20 0.50
AURKB Q96GD4 8/20 0.50
ROCK2 O75116 2/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.41
GFER P55789 1/20 0.41
TSHR P16473 1/20 0.39
HTT P42858 2/20 0.39
SRC P12931 2/20 0.38
GSK3B P49841 2/20 0.38
NTRK1 P04629 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3324249 0.90 MAPT (0.43) AURKAAURKBROCK2NPC1RAB9A
SCHEMBL1054549 0.83 AURKA (0.53) AURKAAURKBSRCNTRK1CYP1A2
SCHEMBL4367242 0.82 AURKA (0.55) AURKAAURKBSRCNTRK1CYP1A2
SCHEMBL1532405 0.81 AURKA (0.62) AURKAAURKBSRCNTRK1CYP1A2
SCHEMBL12656805 0.79 AURKB (0.56) AURKAAURKBSRCGSK3B
SCHEMBL10560991 0.78 TSHR (0.54) ROCK2NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2713578 0.78 MEN1 (0.40) AURKAAURKBROCK2SMN1; SMN2SRC
SCHEMBL2206767 0.77 AURKA (0.60) AURKAAURKBSRCGSK3B
SCHEMBL15725191 0.77 AURKB (0.56) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL13004285 0.77 AURKA (0.41) AURKAAURKBSRCNTRK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140141099-A1 DRUG DISCOVERY METHODS VERTEX PHARMACEUTICALS INCORPORATED 2014-05-22 US disclosed
US-20140141099-A1 DRUG DISCOVERY METHODS VERTEX PHARMACEUTICALS INCORPORATED 2014-05-22 US disclosed
US-20110269732-A1 DRUG DISCOVERY METHODS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-03 US disclosed
US-20110269732-A1 DRUG DISCOVERY METHODS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-03 US disclosed
WO-2008131103-A2 DRUG DISCOVERY METHODS FOR AURORA KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140141099-A1 DRUG DISCOVERY METHODS AURKB, AURKC, AURKA AURKA 3/4885AURKB 1/4885ROCK2 115/4885
US-20110269732-A1 DRUG DISCOVERY METHODS AURKB, AURKC, AURKA AURKA 3/4885AURKB 1/4885ROCK2 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.